"These findings are an important demonstration of the role of dysfunctional RyRs in stress-induced disorders of the central nervous system," said Michael A. Blanar, Ph. D., Chief Scientific Officer of ARMGO Pharma. "The data also suggest the potentially broad utility of Rycal compounds for the treatment of learning and memory impairment in a variety of human pathologies."
In addition to demonstrating the role of the RyR2 isoform in a preclinical model of stress-induced cognitive dysfunction, the data support accumulating evidence that neuronal RyRs are intimately involved in learning and memory and that restoration of normal intracellular calcium homeostasis is important to neuronal cell survival and normal function. The central role of the RyR in neuronal pathology, as well as the downstream consequences of sustained RyR mediated calcium leak and elevated neuronal calcium concentrations, suggest a potentially significant role for RyR-directed therapies in diseases of the central nervous system.
"The lack of novel therapies to address cognitive disorders is a tremendous unmet medical need worldwide," said Sapan Shah, Ph. D., President and Chief Executive Officer of ARMGO Pharma. "Studies from Dr. Marks' laboratory have previously demonstrated compelling evidence for the potential benefit of ARMGO's Rycal program for the treatment of important cardiovascular and musculoskeletal diseases. These new results demonstrate that we may also be able to treat important conditions including PTSD and perhaps other related learning and memory disorders. We are encouraged that these remarkable findings further validate and support ARMGO's efforts to
|SOURCE ARMGO Pharma, Inc.|
Copyright©2012 PR Newswire.
All rights reserved